Form 8-K - Current report:
SEC Accession No. 0000950170-25-093263
Filing Date
2025-07-02
Accepted
2025-07-02 17:30:27
Documents
10
Period of Report
2025-07-01
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K tcrt-20250701.htm   iXBRL 8-K 64206
  Complete submission text file 0000950170-25-093263.txt   177710

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrt-20250701.xsd EX-101.SCH 28388
12 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20250701_htm.xml XML 4710
Mailing Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 251102737
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)